#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Epidermolysis bullosa Cold type haemolytic anaemia Retinopathy of prematurity Splenic marginal zone lymphoma Sexually transmitted disease Vitamin B12 deficiency Lymphangiosarcoma Malignant oligodendroglioma Lennox-Gastaut syndrome Fibrous dysplasia of bone Osteomyelitis Cholestatic pruritus Pleomorphic liposarcoma Non-renal cell carcinoma of kidney Muscular dystrophy More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome Chondrosarcoma metastatic Hairy cell leukaemia recurrent – Life with Disease Familial haemophagocytic lymphohistiocytosis – Trials in Disease Hereditary angioedema – Treatment Extranodal marginal zone B-cell lymphoma (MALT type) – Trials in Disease Isodicentric chromosome 15 syndrome – Diagnostics CADASIL – Treatment Atypical teratoid/rhabdoid tumour of CNS – Treatment Small intestine leiomyosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lumateperone Nadunolimab Clazakizumab Calcium Levofolinate METHYLPHENIDATE Candesartan Cilexetil RIVASTIGMINE Ads-010 Tusamitamab Ravtansine Paltusotine Vx-522 AZD0120 L-Acetylleucine Potato Starch Citicoline Sodium L-Arginine Hydrochloride Zipalertinib Olanzapine Benzylpenicillin Sabatolimab More therapies…

    Learn about Your Condition

    Soft tissue sarcoma Arthralgia Spondylolisthesis B-cell lymphoma recurrent Aplastic anaemia Abortion threatened Lymphangioleiomyomatosis Postoperative wound infection Skin angiosarcoma Type V hyperlipidaemia Hodgkin's disease refractory Lysosomal storage disorder Dyspnoea Laparotomy Prostate cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Bacs-Kiskun Varmegyei Oktatokorhaz

Bacs-Kiskun Varmegyei Oktatokorhaz

Nyiri Ut 38, Kecskemet, 6000, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Ivonescimab
    • Bevacizumab
    • Fluorouracil
    Belgium Czechia France Germany Hungary Italy +2

  • A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • AB521
    • Placebo
    • Cabozantinib
    Czechia France Germany Hungary Italy The Netherlands +3

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    • RLY-2608
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    • Endometrial cancer
    Investigated Drugs:
    • Db-1303
    • Docetaxel
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark Finland France +9

  • Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • GSK5764227
    • Topotecan
    Bulgaria Finland France Germany Greece Hungary +7

  • Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cyclophosphamide
    Belgium Czechia Finland France Germany Greece +8

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Vinorelbine
    • Cemiplimab
    Hungary Poland Portugal Romania Spain

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Doxorubicin Hydrochloride, Liposomal
    • Capecitabine
    France Germany Greece Hungary Italy Poland +1

  • Study of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Raludotatug Deruxtecan
    • Ifinatamab Deruxtecan
    • Docetaxel
    Germany Greece Hungary Italy Poland Spain

  • Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Raludotatug Deruxtecan
    • Ifinatamab Deruxtecan
    • Docetaxel
    Germany Greece Hungary Italy Poland Spain
Previous Page
1 2 3 4 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!